SCHEMBL4990928

SCHEMBL4990928

O=C1Nc2ccc(F)cc2/C1=C\Nc1ccc(CCCCN2CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.47
PDGFRB P09619 6/20 0.46
KDR P35968 6/20 0.46
FGFR1 P11362 2/20 0.46
TLK2 Q86UE8 1/20 0.46
CSF1R P07333 2/20 0.46
FLT1 P17948 2/20 0.46
PDGFRA P16234 1/20 0.46
SCN5A Q14524 1/20 0.45
PAK1 Q13153 4/20 0.44
KIT P10721 4/20 0.44
PIM1 P11309 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
LRRK2 Q5S007 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CRHBP P24387 1/20 0.40
HTT P42858 1/20 0.40
CRHR2 Q13324 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990931 1.00 FLT3 (0.47) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4992442 0.93 FLT3 (0.49) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4992447 0.93 FLT3 (0.49) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4997102 0.93 SCN5A (0.45) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4997104 0.93 SCN5A (0.45) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL6612470 0.92 FLT3 (0.41) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL6612475 0.92 FLT3 (0.41) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4994823 0.91 FLT3 (0.50) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4994821 0.91 FLT3 (0.50) FLT3PDGFRBKDRFGFR1TLK2
SCHEMBL4993690 0.90 PAK1 (0.47) FLT3SCN5APAK1PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PDGFRB 307/4885KDR 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.